BR9915267A - Métodos de tratamento, prevenção ou redução derisco de doença de alzheimer - Google Patents

Métodos de tratamento, prevenção ou redução derisco de doença de alzheimer

Info

Publication number
BR9915267A
BR9915267A BR9915267-3A BR9915267A BR9915267A BR 9915267 A BR9915267 A BR 9915267A BR 9915267 A BR9915267 A BR 9915267A BR 9915267 A BR9915267 A BR 9915267A
Authority
BR
Brazil
Prior art keywords
risk
disease
alzheimer
methods
prevention
Prior art date
Application number
BR9915267-3A
Other languages
English (en)
Inventor
Benjamin Wolozin
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of BR9915267A publication Critical patent/BR9915267A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"MéTODOS DE TRATAMENTO, PREVENçãO OU REDUçãODO RISCO DA DOENçA DE ALZHEIMER". São descritosmétodos de tratamento, prevenção ou redução do risco docomeço da doença de Alzheimer por administração de umaquantidade terapeuticamente efetiva de um inibidor da enzimaredutase 3-hidroxi-3-metilglutaril coenzima A ("inibidor da redutaseHMG CoA") ao paciente que está sob risco de evento coronarianoou cerebrovascular ou sob risco da doença de Alzheimer.
BR9915267-3A 1998-11-13 1999-11-15 Métodos de tratamento, prevenção ou redução derisco de doença de alzheimer BR9915267A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/190,439 US6472421B1 (en) 1998-11-13 1998-11-13 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
PCT/US1999/026979 WO2000028981A2 (en) 1998-11-13 1999-11-15 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor

Publications (1)

Publication Number Publication Date
BR9915267A true BR9915267A (pt) 2001-12-04

Family

ID=22701366

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915267-3A BR9915267A (pt) 1998-11-13 1999-11-15 Métodos de tratamento, prevenção ou redução derisco de doença de alzheimer

Country Status (9)

Country Link
US (1) US6472421B1 (pt)
EP (1) EP1131060A2 (pt)
JP (1) JP2002529500A (pt)
AU (1) AU771254B2 (pt)
BR (1) BR9915267A (pt)
CA (1) CA2350420A1 (pt)
HK (1) HK1040490A1 (pt)
NO (1) NO20012317L (pt)
WO (1) WO2000028981A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease
NZ518822A (en) * 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
WO2002062824A2 (en) * 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid ? precursor disorder
US20020173535A1 (en) * 2001-02-07 2002-11-21 Renshaw Perry F. Cholesterol-lowering agents as treatment for psychological and cognitive disorders
AU2002252664A1 (en) * 2001-04-13 2002-10-28 First Genetic Trust Methods and systems for managing informed consent processes
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
WO2003000372A2 (en) * 2001-06-25 2003-01-03 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
WO2003077896A1 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Drug combination therapy
WO2003086379A1 (en) * 2002-04-12 2003-10-23 Henry Ford Health System Treatment of neural injury and neurodegenerative disease with statins
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
DK2368565T3 (en) 2003-07-03 2015-09-28 Hdl Therapeutics Inc Enrichment of pre-beta lipoproteins, high density
JP2007515464A (ja) * 2003-12-23 2007-06-14 テムレル・リミテッド 医薬組成物用ペレットの製造方法
US20070161700A1 (en) * 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
KR20060135826A (ko) * 2004-03-31 2006-12-29 코와 가부시키가이샤 외용제
CA2630604C (en) * 2005-11-29 2016-01-19 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
ES2330184B1 (es) * 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
JP2021504003A (ja) 2017-11-22 2021-02-15 エイチディーエル セラピューティクス インコーポレイテッドＨｄｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 血漿処理システムの流体回路をプライミングするシステムおよび方法
CA3087207A1 (en) 2017-12-28 2019-07-04 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
AU679675B2 (en) 1992-05-11 1997-07-10 Bayer Corporation Methods for detecting beta amyloid precursor protein processing enzymes
AU7397094A (en) 1993-08-30 1995-03-22 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
US6537987B1 (en) 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US5734054A (en) 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
DE19716120A1 (de) 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
JP2002501887A (ja) 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー アルツハイマー病の治療方法
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein

Also Published As

Publication number Publication date
WO2000028981A3 (en) 2000-11-09
WO2000028981A2 (en) 2000-05-25
CA2350420A1 (en) 2000-05-25
NO20012317D0 (no) 2001-05-10
AU1624100A (en) 2000-06-05
US6472421B1 (en) 2002-10-29
NO20012317L (no) 2001-07-06
EP1131060A2 (en) 2001-09-12
JP2002529500A (ja) 2002-09-10
HK1040490A1 (zh) 2002-06-14
AU771254B2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
BR9915267A (pt) Métodos de tratamento, prevenção ou redução derisco de doença de alzheimer
BR9915800A (pt) Produto terapêutico para supressão dos ruìdos de ronco
AU2001257451A1 (en) Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
DK0738512T3 (da) Fremgangsmåde til forebyggelse af et andet hjerteanfald ved anvendelse af en HMG coenzsym A reduktasehæmmer
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
HK1126957A1 (en) Krill extracts for prevention and/or treatment of cardiovascular diseases
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
TNSN04167A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
BR9913831A (pt) Processo para tratamento de arteriosclerose empregando um inibidor de ap2 e combinação
PT97660A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina
MX9606503A (es) Inhibidores de pla2 y su uso para la inhibicion de la absorcion del colesterol interno.
HRP20050534A2 (en) Prevention and treatment of alzheimer's disease
BR9813542A (pt) Combinações de estatina-éter carboxialquìlico
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
NO20000771D0 (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
HUP0004647A2 (hu) Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
DE69730045D1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
BR0210426A (pt) Metil análogo de sinvastatina para inibição de hmg-coa redutase e processo de obtenção do mesmo
EP1321146A3 (en) Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired